**Patient Discharge Summary**

**Patient Details:**  
- **Name:** John Doe  
- **Age:** 45 years  
- **Sex:** Male  
- **Admission Date:** November 5, 2023  
- **Discharge Date:** November 12, 2023  
- **Hospital:** St. Mary's Infectious Diseases Unit  

**Chief Complaint:**  
The patient presented to the emergency department on November 5, 2023, with acute onset of high fever, severe muscle aches, cough, and generalized weakness. He reported the symptoms started approximately 48 hours prior to admission.

**Medical History:**  
- No known drug allergies.
- Past medical history of hypertension, controlled with medication.
- No prior history of influenza vaccination.

**Physical Examination upon Admission:**  
- Temperature: 102.4°F (39°C)  
- Blood Pressure: 130/85 mmHg  
- Respiratory Rate: 22 breaths/min  
- Oxygen Saturation: 94% on room air  
- Examination revealed clear lung fields, no rash, and normal heart sounds.

**Laboratory and Diagnostic Testing:**  
- Rapid antigen test for influenza conducted on November 5, 2023, returned positive for Influenza A.
- RT-PCR test for influenza confirmed the subtype as H3N2.
- Chest X-ray performed on November 5, 2023, showed no evidence of pneumonia.
- Pulse oximetry consistently showed readings above 94% on room air throughout the stay.

**Treatment Summary:**  
Given the diagnosis of influenza A (H3N2) and considering the patient's high-risk status due to hypertension, antiviral therapy was initiated within 24 hours of symptom onset.

1. **Oseltamivir** was prescribed at a dose of 75 mg orally twice a day for a duration of 5 days, starting on November 5, 2023. The patient tolerated the medication well without any noted side effects.

2. Symptomatic treatment included:
   - Acetaminophen 650 mg orally every 6 hours for fever and myalgias, avoiding aspirin due to the risk of Reye's syndrome.
   - Adequate hydration and bed rest were advised.

3. The patient was monitored for signs of secondary bacterial infection or complications such as pneumonia, but none were observed during the hospital stay. Oxygen therapy was not required.

**Progress:**  
The patient showed significant improvement with resolution of fever by November 8, 2023, and a marked reduction in cough and muscle aches. By November 11, 2023, the patient reported feeling much improved, with only mild residual weakness.

**Discharge Instructions:**  
1. Complete the full course of Oseltamivir as prescribed.
2. Continue rest and hydration at home.
3. Avoid contact with vulnerable individuals until fully recovered.
4. Follow-up with primary care physician in 7 days or sooner if symptoms recur or worsen.
5. Consider annual influenza vaccination in the future to reduce the risk of complications from influenza.

**Follow-Up:**  
John Doe was advised to schedule a follow-up appointment with his primary care physician on November 19, 2023, for post-recovery assessment and to discuss influenza vaccination.

**Summary:**  
John Doe, a 45-year-old male, was admitted to the infectious diseases unit with a diagnosis of influenza A (H3N2). He was treated with Oseltamivir and symptomatic care, showing significant improvement and was discharged on November 12, 2023, with instructions for continued rest, hydration, and follow-up care.